Free tool
FAERS Monitor: Invega Hafyera
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 207946 or its brand name (Invega Hafyera, Paliperidone Palmitate). Reports on generic versions are filed under their own applications.
Reports
8,538
Serious
5,139
60% of reports
Hospitalization
2,454
Death reported
599
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective842
- off label use790
- hospitalisation646
- schizophrenia556
- condition aggravated508
- product dose omission issue407
- therapeutic response decreased342
- death319
- psychotic disorder317
- weight increased307
- suicide attempt264
- dyskinesia260
- sedation260
- hallucination, auditory244
- inappropriate schedule of product administration238
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2006 | 2 |
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 5 |
| 2010 | 7 |
| 2011 | 15 |
| 2012 | 76 |
| 2013 | 74 |
| 2014 | 49 |
| 2015 | 126 |
| 2016 | 445 |
| 2017 | 769 |
| 2018 | 609 |
| 2019 | 609 |
| 2020 | 504 |
| 2021 | 592 |
| 2022 | 1,262 |
| 2023 | 1,107 |
| 2024 | 962 |
| 2025 | 786 |
| 2026 | 537 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,045,621 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| schizophreniaSignal | 556 | 118.1 | 108.7 | 61,516 |
| hallucination, auditorySignal | 244 | 38.4 | 33.9 | 8,722 |
| psychotic disorderSignal | 317 | 26.7 | 24.0 | 7,751 |
| sedationSignal | 260 | 24.7 | 21.9 | 5,835 |
| dyskinesiaSignal | 260 | 15.9 | 14.1 | 3,588 |
| therapeutic response decreasedSignal | 342 | 14.0 | 12.6 | 4,094 |
| suicide attemptSignal | 264 | 10.8 | 9.6 | 2,326 |
| hospitalisationSignal | 646 | 10.4 | 9.7 | 5,494 |
| condition aggravatedSignal | 508 | 4.1 | 3.8 | 1,213 |
| product dose omission issueSignal | 407 | 3.4 | 3.1 | 701 |
| weight increasedSignal | 307 | 3.4 | 3.0 | 517 |
| inappropriate schedule of product administrationSignal | 238 | 3.3 | 2.9 | 373 |
| off label useSignal | 790 | 2.2 | 2.1 | 553 |
| drug ineffective | 842 | 1.6 | 1.5 | 187 |
| death | 319 | 0.9 | 0.8 | 3 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.